Sage Journals: Discover world-class research

Retricted access

Research article

First published 2008-02

Comparison Between 2D and 3D Dosimetry Protocols in 90 Y-Ibritumomab Tiuxetan Radioimmunotherapy of Patients with Non-Hodgkin's Lymphoma

Karine Assié, Arnaud Dieudonné, Isabelle Gardin [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2008-10

Estimates of Radiation-Absorbed Dose to Kidneys in Patients Treated with 90 Y-Ibritumomab Tiuxetan

Sébastien Baechler, Robert F. Hobbs, Andrew R. Prideaux [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2012-03

Three-Dimensional Patient-Specific Dosimetry in Radioimmunotherapy with 90 Y-Ibritumomab-Tiuxetan

Marco D'Arienzo, Francesco Cicone, Laura Chiacchiararelli [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2005-04

Yttrium-90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Gregory A. Wiseman, Thomas E. Witzig

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2007-10

Imaging of the Distribution of 90 Y-Ibritumomab Tiuxetan in Bone Marrow and Comparison with Pathology

Jeremy Coulot, Valérie Camara-Clayette, Marcel Ricard [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Case report

First published 2009-04

The Role of Dosimetry in the High Activity 90 Y-Ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution

Demetrio Aricò, Chiara Maria Grana, Anna Vanazzi [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2007-02

Dosimetry in Myeloablative 90 Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results

Carlo Chiesa, Francesca Botta, Erika Di Betta [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2013-03

Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving 90 Y-Ibritumomab-Tiuxetan

Francesco Cicone, Marco D'Arienzo, Andrea Carpaneto [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2013-06

Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma

Christos Vaklavas, Ruby F. Meredith, Sui Shen [...]

Cancer Biotherapy and Radiopharmaceuticals

Retricted access

Research article

First published 2003-04

Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

Gregory A. Wiseman, Bryan R. Leigh, William D. Erwin [...]

Cancer Biotherapy and Radiopharmaceuticals

Search results